Key result
Rivaroxaban and apixaban intake reduced coagulation factor levels in healthy males, including FVIII:C (mean difference -38 IU/dL, 95% CI -43 to -33 for rivaroxaban), FXI:C, FXII:C, and d-dimer.
Why the study?
Do rivaroxaban and apixaban influence coagulation factor levels in healthy male individuals?
RCT (n=12)
Do rivaroxaban and apixaban influence coagulation factor levels in healthy male individuals?
Mean Difference: -38 (95% CI -43–-33)
Rivaroxaban and apixaban significantly lower measured levels of FVIII:C, FXI:C, FXII:C, and d-dimer, indicating that timing of blood sampling relative to drug intake must be considered when assessing VTE recurrence risk.
BACKGROUND: Prediction models for venous thromboembolism recurrence will likely be improved by adding levels of coagulation factors. Risk assessment is ideally performed during anticoagulant treatment, however, the influence of direct oral anticoagulants on coagulation factors is uncertain. OBJECTIVE: To assess the influence of rivaroxaban and apixaban on several coagulation factor levels. METHODS: In two crossover trials we assessed the influence of rivaroxaban and apixaban intake on factor (F)VIII, FXI and FXII-activity and fibrinogen, von Willebrand factor (VWF:Ag), and d-dimer levels. At three sessions with a washout period in between, blood was taken from 12 healthy male individuals immediately before intake of rivaroxaban 15 mg twice daily (n = 6) or apixaban 10 mg twice daily (n = 6) and three hours after the last intake. RESULTS: Overall, measured levels were lower after rivaroxaban/apixaban intake. The paired mean difference after rivaroxaban intake was -38 IU/dL (95% CI -43; -33) for FVIII:C, -29 U/dL (95% CI -45; -12) for FXI:C, -22 IU/dL (95% CI -43; -1) for FXII:C, -0.11 g/L (95% CI -0.25; 0.03) for fibrinogen, -7 IU/dL (95% CI -18; 3) for VWF:Ag, -27 ng/mL (95% CI -50; -4) for d-dimer and -0.36 (95% CI -0.57; -0.15) for Ln d-dimer. After apixaban intake this was -29 IU/dL (95% CI -38; -21) for FVIII:C, -29 IU/dL (95% CI -36; -22) for FXI:C, -19 IU/dL (95% CI -24; -15) for FXII:C, -0.18 g/L (95% CI -0.33; 0.03) for fibrinogen, -52 ng/mL (95% CI -100; -4) for d-dimer, 0.25 (-0.60; 0.09) for Ln d-dimer and 1 IU/dL (95% CI -7; 9) for VWF:Ag. CONCLUSION: FVIII:C, FXI:C, FXII:C, and d-dimer measurements were influenced by rivaroxaban/apixaban intake, while fibrinogen and VWF:Ag were not.
No takes yet. Share an insight, caveat, or question.
Scheres et al. (2018) conducted an RCT in Healthy (n=12). Rivaroxaban and apixaban vs. Baseline (immediately before intake) was evaluated on FVIII:C level (MD -38 IU/dL, 95% CI -43; -33). Rivaroxaban and apixaban intake reduced coagulation factor levels in healthy males, including FVIII:C (mean difference -38 IU/dL, 95% CI -43 to -33 for rivaroxaban), FXI:C, FXII:C, and d-dimer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: